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We sought to assess the quality of dermatological systematic reviews and to identify factors 
that predict high methodological quality. We searched for all systematic reviews published in 
2017 using PubMed, Epistemonikos, and the Cochrane Database of Systematic Reviews. We 
included studies identified as systematic reviews or meta-analysis in the title or abstract and 
dealing with a dermatological topic. Study selection, data extraction, PRISMA and AMSTAR 
2 rating were carried out independently by two authors. Based on AMSTAR 2, confidence in 
systematic reviews results was classified as high, moderate, low or very low. We included 732 
studies. We describe a random sample of 140. The overall rating of confidence in the results 
according AMSTAR 2 tool was high or moderate for nine reviews (6%). Twenty (15%) had a 
registered protocol. Independent factors associated with AMSTAR 2 moderate or high rating 
were publication in a journal where PRISMA is mandatory (odds ratio (95% confidence 
interval) = 27.0 (1.4-528) and journal impact factor (OR 1.9 (1.3-3)) for each increase in one 
more point. The observation that 90% of published dermatology systematic reviews are of 
very low quality is alarming. Review registration in PROSPERO and full reporting according 
to PRISMA should be mandatory for publication. 


















A systematic review (SR) is a review of a precisely defined subject using systematic methods 
to identify, select and analyze relevant research (Higgins et al. 2019). SRs have become over 
the years one of the main tools for clinicians, guideline authors and public health agencies to 
make more informed decisions. The number of SRs published each year is constantly 
increasing (Chalmers and Fox 2016). Ioannidis reported an increase of 2,728% for systematic 
reviews between 1991 and 2014, almost 20 times greater than the increase in all indexed 
publications (Ioannidis 2016). The results and conclusions of SRs are relevant for helping in 
the decision-making process only if their reporting is complete enough to guarantee 
transparency and if the quality is good enough to prevent bias. 
The Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) statement is an 
evidence-based minimum made of 27 items for reporting in systematic review and meta-
analysis (Moher et al. 2009). Many journals have endorsed the PRISMA statement and 
request authors submitting a SR to follow PRISMA and in some cases include a PRISMA 
checklist. The methodological counterpart is covered by the AMSTAR 2 tool (Shea et al. 
2017). This tool is made of 16 questions covering different aspects of methodology of 
systematic reviews.  
The aims of a priori registration of systematic reviews are to prevent reporting bias and 
duplication of efforts, and to promote transparency in the review process. PROSPERO is the 
international register for systematic reviews protocols (Page et al. 2018). Protocol registration 
of the systematic review requires a precise research question, inclusion criteria and prespecified 
primary and secondary outcomes. Protocols of Cochrane Reviews are published in both the 
Cochrane Library and PROSPERO. 
Deficiencies in the conduct and reporting of SRs have been highlighted in general (Pussegoda 
et al. 2017) as well as in specific specialties such as pediatric surgery (Cullis et al. 2017) or 
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urology (Xia et al. 2017). A recent analysis of quality of reporting of SRs according to PRISMA 
published from 2013 to 2017 in the five highest-impact dermatology journals concluded that 
reporting was often inadequate but had improved over time (Croitoru et al. 2019). Reporting 
quality is important, but it is not the same as study quality. Although the two are related in that 
good reporting is a pre-requisite to assess study quality, it does not mean that a well reported 
review is necessarily a good quality review. It is important therefore to assess the quality of 
published dermatology systematic reviews as well as the completeness of reporting.  
The main objective of this study was to assess study quality using the AMSTAR 2 tool and 




For the 6,117 SRs retrieved through database searching, 951 duplicates were removed, and 
4405 were excluded. Among the 732 (386 intervention; 346 others) corresponding to our 
selection criteria, a sample of 140 SRs was randomly selected (68 interventional and 72 non-
interventional) and included in the final analysis. The selection process and reasons for 
exclusion are summarized in Figure 1. A list of excluded studies after full text analysis is listed 
in appendix S2. 
 
Characteristics of included systematic reviews 
The characteristics of the randomly selected SRs are summarized in Table 1. The majority of 
the 140 SRs did not include a MA (n=73, 53%). The most frequent type of non-interventional 
reviews were epidemiological reviews (n=49, 35%). The most frequent topic was inflammatory 
skin diseases (n=49, 35%). The median number of authors was 5 (1-29). Determined by the 
country of first author, reviews were most commonly from European countries 43 (31%). 
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In total, the 140 SRs were published in 89 different journals; the four most frequent journals 
were The British Journal of Dermatology, The Journal of the American Academy of 
Dermatology, The Journal of the European Academy of Dermatology and Venereology, and 
The Cochrane Database of Systematic Reviews (n=7 each). The mean impact factor of journals 
was 3.3 (0.46; 14.1). One third of SRs (n= 46; 33%) were published in journals that explicitly 
required authors to follow the PRISMA statement, and 29 (21%) were in journals that suggested 
authors followed the PRISMA statement. In 85 SRs (61%), authors reported that they had 
reported the review according to PRISMA but five (4%) provided the checklist.  
 
 
Quality of the methodology of systematic reviews according to AMSTAR 2 
The overall rating of confidence in the results of the SR according to the AMSTAR 2 tool was 
high (none or one non-critical weakness) for eight reviews (6%), moderate (more than one 
non-critical weaknesses) for one (1%), low (one critical flaw with or without critical 
weakness) for five (4%) and very low (more than one critical flaw with or without critical 
weakness) for 126 (90%). All Cochrane Reviews were associated with a high overall rating of 
confidence in the results.  The proportion of review with a moderate to high level of 
confidence (nine out of 140, 6%) was similar when limiting the analysis to SRs including a 
MA (five out of 56, 7%). When limited to intervention reviews, the proportion of reviews 
with a moderate to high level of confidence was 12 % (8 /68). 
In 69% (n=97/140), of the SRs, four or more steps considered as one of the seven critical 
domains (Q2, 4, 7, 9, 11, 13 and 15) of the AMSTAR 2 tool were not performed adequately. 
A statement of the establishment of review methods prior to the conduct of the review (Q2) 
was given for 21 SRs (15%). Concerning the search strategy (Q4), 38 (27%) of the reviews 
provided a comprehensive search strategy, and of these 11 (8%) searched in other sources, 
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including grey literature. A list of excluded studies and justification of exclusion (Q7) was 
provided in 26 (19%) of SRs. Risk of bias assessment of individual studies (Q9) was done 
with a satisfactory technique in 44 SRs (31%) and 36 SRs (26%) assessed the impact of risk 
of bias in individual studies on the results of the review (Q13). Finally, among the 67 SRs 
with MA, 45 (32%) used an appropriate method for combining data (Q11), and 38 (27%) 
carried out an adequate investigation of publication bias and discussed its likely impact on the 
results of the review (Q15).  
Figure 2 represents the rate of yes or partial yes for each AMSTAR 2 question. Results for 
each question are available in table S4. 
 
Factors associated with a moderate to high level of confidence in the results of SRs 
according AMSTAR 2 
In univariable analyses, PRISMA endorsers, journals with an EBM section, Cochrane Reviews, 
higher impact factor journals, registered protocol and interventional SRs were associated with 
a moderate to high AMSTAR 2 overall rating (Table 2). After testing the correlation between 
these variables, journals with an EBM section, Cochrane Reviews and protocols were excluded 
(r>0.5). In a multivariable analysis, independent risk factors associated with a moderate to high 
level of confidence were publication in a journal where PRISMA was mandatory (odds ratio 
(95% confidence interval) = 27 (1.4-528) and journal impact factor (OR1.92 (1.3-3) for each 
higher point of impact factor). 
We did not include PRISMA adherence as a potential associated factor because there is no 
method for assessing an overall score as there is for AMSTAR. All SRs with a moderate to high 
AMSTAR 2 score had fulfilled 20 or more items. The distribution is wider for SRs with low to 
very low AMSTAR. Indeed 42 % fulfilled more than 20 items, 67% between 10 and 20 and 
22% less than 20 items. 
Quality of reporting of systematic reviews according PRISMA checklist 
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Seventy-two (51%) of the 140 analyzed reviews reported at least two thirds of the required 
items of the PRISMA checklist. All the items of PRISMA checklist were reported in only 
three SRs. For intervention reviews, 42 out of 68 (62%) reported at least two thirds of the 
required items of the PRISMA checklist. Figure 3 shows the proportion of SRs that reported 
each PRISMA item. The five items reported in less than one third of the reviews were: Item 
five related to protocol redaction, Items 15 and 22 corresponding respectively to methods and 
results of publication bias and outcome reporting bias assessment; and I16 and I23 
corresponding respectively to methods and results of sensitivity or subgroup analyses.  A 
clear definition of the question (I4) was reported in 72 (51%) of the SRs. A table with the 
results for each item is available in table S3. 
 
DISCUSSION 
Main findings  
Our study showed that methods and reporting of a large number of systematic reviews 
published in 2017 in dermatology field were poor. In 2017, 732 dermatological publications 
were named as systematic reviews and /or a meta-analysis by their authors in the title or 
abstract. In our random sample of 140 reviews, the proportion with an AMSTAR 2 overall 
rating of moderate to high confidence in the results was 6% (n=9), and of these 140 SRs, half 
reported two thirds of the items in the PRISMA checklist. These disappointing results have to 
be balanced by the fact that we considered all types of SRs, not only intervention SRs, and 
reviews published in all journals whatever the impact factor. Indeed, intervention SRs had 
slightly better results, with 12% achieving moderate to high AMSTAR 2 overall ratings and 
68% (42/68) reporting two thirds of PRISMA items.  
The two independent factors associated with a moderate to high confidence in the results of a 
SR according AMSTAR 2 were publication in a journal where PRISMA was mandatory  and 
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a higher journal impact factor. We did not identify registration of a protocol as an independent 
risk factor in this study. A recent study assessing adherence to PRISMA of SRs published 
between 2013 and 2017 in the five highest impact dermatology journals found an 
improvement of reporting over time and an independent association between protocol 
registration and better reporting  (Croitoru et al. 2019). 
Each of the seven methodological steps considered as critical in the AMSTAR 2 tool was 
adequately performed in a maximum of 32% and a minimum of 13% of the reviews. 
Registration allows reviewers and readers to verify the concordance between what was 
planned and what was done. Indeed, it has been previously demonstrated that post hoc 
alterations in the choice of inclusion/ criteria and analytical models for meta-analysis can 
result in major changes in the results (Palpacuer et al. 2019).  Rigorous searching of all 
relevant articles regardless of language is also critical in order to avoid including only 
published studies having more frequently positive results (Le Cleach et al. 2016). A previous 
study that re-analyzed meta-analyses that including unpublished FDA data almost always 
modified the results (Hart et al. 2012). In our study, 27 SRs (19%) searched for studies in at 
least two databases and provided key words and/or search strategy and justified publication 
restriction. 
 
Strengths and limitations 
Strengths of our study were the registration of our protocol, a wide search for studies, and a 
double independent study selection and data extraction. In addition, we used the AMSTAR 2 
tool that is associated with an overall rating algorithm based on a distinction between critical 
and non-critical methodological points. The inclusion of all type of SRs based on the title or 
abstract with no limitation (language, type of SR, journal) ensured strong external validity of 
our results. Our study had some limitations. For practical reasons, we analyzed a sample of 
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the SRs published in 2017. However, this sample was randomly selected and thus likely to be 
representative. Regarding deviation from the protocol, we added in an analysis of publication 
in a journal with PRISMA mandatory request, protocol registration and interventional SR. 
These items should be considered as post hoc analyses. It is also worth pointing out that 
although PRISMA and AMSTAR 2 are used for all types of SR/MA, they were initially more 
dedicated towards intervention review and adaptation of some questions of for non-
intervention reviews was done. A new version of PRISMA taking account of these new 
developments in systematic reviews is in on the way (Page et al. 2020). 
 
Relationship between quality and quality of reporting 
The discrepancies of results between PRISMA and AMSTAR 2 highlighted that adequate 
reporting did not mean that methodology was appropriate. For example, we considered that 
information was reported in 86% of SRs for the PRISMA item “Describe all information 
sources in the search and date last searched”, but only 27% were rated Yes or partial Yes for 
the related question of AMSTAR “Did the review authors use a comprehensive literature 
search strategy”, because of absence of justification of publication restriction and of absence 
of search for unpublished studies.  
 
How our results compare with other medical disciplines 
A study assessing SRs in orthodontics published between 2012 and 2016 found that the 
37/182 (20.3%) of reviews associated with a registered protocol were associated with a higher 
AMSTAR score compared to those with non a priori registered protocol (Sideri et al. 2018). 
Our results (13% of SR with a registered protocol) were comparable to those in the 
orthodontic fields, and to those of a study assessing a sample of all SRs published from 1996 
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to 2010 that found  6% (102/1741) of SRs providing information on protocol (Le Cleach et al. 
2016; Pussegoda et al. 2017).  
 
What needs to be done? 
 Given the confidence that readers and guideline writers often place in systematic reviews 
based on the quoted position of systematic reviews on the top of evidence hierarchy, journal 
reviews of this type of article should be especially stringent, and should always include 
prospective registration and a review of PRISMA and at least a reviewer with experience in 
SR methodology. For full presentation of methods and results of systematic reviews, journals 
should allow and encourage  additional important data to be presented in an online 
supplementary appendix that should include PRISMA checklist as a mandatory item.  
It would be useful for harmonization for any future versions of PRISMA to include some key 
items of AMSTAR such as searching for unpublished studies, justification of deviations 
between protocol and review, a list of excluded studies and justification and source of funding 
of included studies. 
 
Implications for future research 
The poor overall quality of dermatology systematic reviews warrants the development of a 
constructive intervention study to encourage dermatology journal editors that accept systematic 
reviews to improve the quality and reporting of systematic reviews, and following up that 
intervention with a repeat of the present study to monitor whether things then improve. It is also 
important to define by consensus what the minimum criteria should be to call a review a 
systematic review. 
 
MATERIALS AND METHODS  
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This review is reported according to the Preferred Reporting Items for Systematic reviews and 
Meta-analyses (PRISMA) statement. The PRISMA checklist is available in table S1. The study 
protocol was registered in PROSPERO on 23/05/2018, [CRD42018093856]. 
 
Literature search  
The search was performed on 11th May 2018 on PubMed, Epistemonikos, and the Cochrane 
Database of Systematic Reviews for articles published in 2017. 
For PubMed, relevant MeSH terms relating to dermatology and skin disease were included in 
the search. As well as exploding the MeSH term "Skin and Connective Tissue Diseases" to 
include all the subsidiary MeSH Terms, MeSH terms for other skin diseases not covered by this 
MeSH term were used, including terms for the major skin cancers. In addition, for all three 
databases a list of free text terms relating to dermatology and major skin diseases was compiled 
based on the major skin disease terms included in the British Association of Dermatologists 
(BAD) Diagnostic Index.   
In PubMed, the search was combined with the built-in Clinical Queries systematic review filter, 




All published studies identified as an SR or MA in their title and/or abstract and concerning a 
dermatologic disease were included.  Both reviewers followed the table of contents of the 
Rook’s Textbook of Dermatology in order to determine if the reviews dealt with dermatology 
(Griffiths et al. 2016). There were no exclusion criteria for the type of studies included in the 




Study selection and data extraction 
Each selection and extraction step was performed by two reviewers independently (LLC, CM, 
SA, SS, IGD, CP), with referral to a third reviewer in case of disagreement. Using Covidence 
(https://www.covidence.org/home), reviewers first screened each title, then abstracts, and then 
full text articles. For feasibility reasons, we undertook a sample size calculation, using a 
binomial exact test. We chose a random sample of 140 as it would lead to reasonable precision 
in terms of 95% confidence intervals for most of the anticipated outcomes. We classified the 
included reviews as interventional or non-interventional, and performed a stratified random 
sampling (interventional and non-interventional) of 20 per cent of the included reviews by 
assigning a computer-generated random number to each SR.  
The data extraction on the 140 randomly selected studies was carried out a standardized 
extraction form.  
 
Quality assessment 
PRISMA and AMSTAR 2 checklists (Table S2) were completed independently by two authors. 
For PRISMA, we gave a rating of non-applicable (NA) for items concerning MA if there was 
no MA in the review. For AMSTAR 2, for non-interventional reviews we rated question 1 
regarding PICO as “yes” for reviews with a clear and precise research question, and for reviews 
including studies others than RCTs or NRSIs we rated “yes” for question 9 on risk of bias 
assessment if a validated tool with a reference was used.  
 
Outcomes 
Our primary outcome was the proportion of SRs with a high, moderate, low or very low overall 
confidence rate in their results according to the AMSTAR 2 tool. High level of confidence is 
defined as none or one non-critical weakness, moderate level is defined as more than one non-
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critical weakness, low level is defined as one critical flaw with or without critical weakness, 
and finally critically low level of confidence is defined as more than one critical flaw with or 
without critical weakness.5Seven items of AMSTAR 2 are considered as critical domains: 
registered protocol, adequacy of the literature search, justification for excluding individual 
studies, individual studies risk of bias, appropriateness of meta-analytical methods, 
consideration of risk of bias when interpreting the results and assessment of presence and 
impact of publication bias. 
Our secondary outcome was the proportion of SRs that fulfilled the required PRISMA items 
(27 for SRs including a MA and 23 for SRs without MA).  
We also assessed factors associated with high or moderate in comparison to low or very low 
levels of confidence according to the AMSTAR rating. Prespecified factors were 
pharmaceutical funding Y/N, EBM or systematic review section, Cochrane systematic review 
Y/N, and journal name. We added a further two non-prespecified factors during the analysis: 
we changed journal name for impact factor (because of the very high number of distinct 
journal names precluding any analysis) and we added PRISMA endorsement, protocol 
registration, and intervention reviews that were considered during the review process as other 
strong potential factors. 
 
Data synthesis 
Data were described as mean± standard deviation (SD) or median (interquartile range, 25th-
75th percentiles) for continuous data, depending on distribution normality, and as number (%) 
for categorical data.  
Assessment of significant differences between a high or moderate AMSTAR 2 score and 
journals’ characteristics (impact factor (2019, Journal Citation Reports), PRISMA 
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endorsement) were based on the Mann-Whitney test for quantitative data and on the χ² or 
Fisher’s exact test for categorical data as appropriate.  
Factors associated with a high or moderate AMSTAR 2 score were determined by a logistic 
regression model. In univariable analyses, the following factors were searched for association 
with high or moderate AMSTAR 2 rating: pharmaceutical funding vs none or institutional, 
inclusion of a protocol, journal that endorsed PRISMA, journal with Evidence Based Medicine 
(EBM section) or dedicated to SRs, Cochrane Review, and type of SR (intervention vs others). 
The strength of correlations between previous variables was determined by calculating 
Pearson’s coefficient r; variables with r<0.50 were entered into the selection process for the 
final multinomial logistic regression model by upward stepwise method based on Akaike 
Information Criterion (AIC).  
Two-tailed p values less than 0·05 were considered significant. Statistical analyses were 
performed using Stata software version 14.1 (StataCorp LP, College Station, TX, USA) 
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Table 1. Characteristics of the 140 appraised systematic reviews (SRs) 
Type of SR  
Intervention 68 (49) 
Epidemiological 49 (35) 
Multiple reviews 15 (11) 
Diagnostic test accuracy 3 (2) 
Genetic reviews 2 (1) 
Type of studies included in SR  
Only RCT 32 (23) 
Only observational studies 42 (30) 
RCT & observational studies 17 (12) 
Only cases 19 (14) 
All (RCT & NRSI & cases or NRSI & cases or others) 30 (22) 
Presence of meta-analysis  
SR without MA 73 (53) 
Classical MA 65 (46) 
Network MA 2 (1) 
Number of studies per SR (median, range) 29 (0-351) 
SR without MA 20 (0-204) 
SR with MA 14 (4-128) 
Dermatologic diseases  
Inflammatory 49 (35) 
Neoplastic, Proliferative and Infiltrative Disorders Affecting the Skin 20 (14) 
Infections & Infestations 16 (11) 
Skin Disorders Associated with Specific Cutaneous Structures (including acne, rosacea, 
hidradenitis suppurativa…) 
16 (11) 
Skin Disorders Caused by External Agents 13 (9) 
Metabolic and Nutritional Disorders Affecting the Skin 6 (4) 
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Vascular Disorders Involving the Skin 5 (4) 
Systemic Disease and the Skin 4 (3) 
Skin Disorders Associated with Specific Sites, Sex and Age  4 (3) 
Aesthetic Dermatology 2 (1) 
Genetic Disorders Involving the Skin  2 (1) 
Psychological, Sensory & Neurological 2 (1) 
Multiple 1 (1) 
Protocol  
Yes, and registered  21 (15) 
Yes, but not registered 7 (5) 
PRISMA statement  
Declared it was followed  55 (39) 
Provided PRISMA checklist 5 (4) 
Sources of funding  
Not declared 42 (30) 
None 49 (35) 
Institutional 39 (28) 
Private 10 (7) 
Number of authors /SR (median, range) 5 (1-29) 
Country of first author   
Europe 43 (31) 
USA 34 (24) 
China 23 (16) 
Others 40 (29) 
Number of studies including as authors  
Institutional professionals  140 (100) 
Employees of pharmaceutical companies 4 (3) 
Private practitioners 4 (3) 
COI  
Declared with COI 24 (17) 
Declared without COI  103 (74) 
Not declared 13 (9) 
Number of SRs published in journals   
With EBM section 15 (11)  
Dedicated to systematic review (not Cochrane) 1(1) 
Cochrane 7 (5) 
With PRISMA mandatory in guidelines for authors 39 (28) 
With PRISMA suggested in guidelines for authors 29 (21) 
 
Data are n (%), indicated when different 




Table 2. Factors associated with a moderate or high AMSTAR 2 overall rating  
 


















OR 95% CI  
 
Multivariable   
analysis  
P 
Publication in a  
journal with  
PRISMA 
mandatory  
8(89) 39(30) 19 (2.3-156) 0.006 27 (1.4-528) 0.03 
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No or institutional 
funding 
8(89) 80(61) 0.2 (0.02-1.6) 0.1   
Protocol registered  9(100) 12 (9) 112 (16.3-inf) 0.0000   
Journal with EBM  
Section  
8(89) 7(5) 142 (16-1297) 0.000   
Cochrane 7(78) 0(0) 391 (47-inf) 0.0000   
Interventional 8(89) 60 (46) 9.5(1.2-77.9) 0.004   












Table S1: PRISMA checklist of the review 
Appendix S1: Search equation 
Table S1: AMSTAR 2 tool 
Appendix S2: List of excluded studies 
Table S3: Rate of completion for each item of PRISMA checklist for the 140 analyzed SRs 
 





Figure 1. Prisma Flow diagram 
Figure 2. Rate of yes or partial yes for each AMSTAR question 
Figure 3. Rate of completion for each item of PRISMA checklist for the 140 analyzed 
Figure 4. Proportion of SRs according number of fulfilled PRISMA item 
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